| | Clinically relevant downstream effects |
| Toxin genes | | entDa, seba | Staphylococcal enterotoxins (SE-B and D) which act as superantigens | hla, hld, hlgA, hlgB, hlgC | Cytotoxins | Virulence genes | | aur, cap8A, cap8B, cap8C, cap8D, cap8F, cap8G, cap8L, cap8N, cap8M, cap8O, chp, geh, sbi, scn, sspB, sspC | Disruption of host complement activity, phagocytosis, and/or immune cell chemotaxis | ebpS, fnb, sdrC | Host tissue adherence | esaA, esaB, esaC, essB, essC, esxA, esxB | Virulence proteins via unclear mechanisms, perhaps modulate host cell apoptosis | hysA, sak | Tissue degradation and invasion | icaA, icaB, icaR | Biofilm formation | isdA, isdB, isdD, isdF, isdG | Iron acquisition | MW0023 | Immune modulation | srtB | Modification of bacterial surface proteins | sspA | Modification of bacterial enzymes and cleavage of immunoglobulin G |
|
|